ストックスクリーナーアプリを入手
0.00
100.00%
-2.0301
前日終値:
$2.0301
開ける：
$0
24時間の取引高:
0
Relative Volume:
0.00
時価総額：
$35.38M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-100.00%
1か月 パフォーマンス:
-100.00%
6か月 パフォーマンス:
-100.00%
1年 パフォーマンス:
-100.00%
1日の値動き範囲:
$0.00
$0.00
1週間の範囲:
$0.00
$0.00
52週間の値動き範囲:
$0.00
$4.74
Mural Oncology Plc Stock (MURA) Company Profile
MURA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MURA
Mural Oncology Plc
|
0.00 | 35.38M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Mural Oncology Plc Stock (MURA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-25 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-25 | ダウングレード | Raymond James | Strong Buy → Outperform |
| 2024-06-28 | 開始されました | Rodman & Renshaw | Buy |
| 2024-04-04 | 開始されました | Morgan Stanley | Overweight |
Mural Oncology Plc (MURA) 最新ニュース
Will Mural Oncology plc stock outperform Nasdaq indexQuarterly Risk Review & AI Powered Trade Plan Recommendations - ulpravda.ru
How Mural Oncology plc stock compares to growth peersDollar Strength & Breakout Confirmation Alerts - ulpravda.ru
Retail Trends: Is Mural Oncology plc stock positioned for digital transformationGlobal Markets & Daily Oversold Stock Bounce Ideas - ulpravda.ru
Net debt of Mural Oncology Plc – LS:A3EE4M - TradingView — Track All Markets
Will Mural Oncology plc stock benefit from automation2026 world cup usa national team semifinals goalkeepers pressing system group prediction breakdown - ulpravda.ru
Return on invested capital % of Mural Oncology Plc – BER:IELK2BOB - TradingView — Track All Markets
XOMA Royalty and Takeda Execute Strategic Royalty Sharing Transaction and Amend Existing Agreement for Mezagitamab - marketscreener.com
Drug royalties reshuffled as XOMA trades part of one for nine experimental drugs - Stock Titan
Net margin % of Mural Oncology Plc – BER:IELK2BOB - TradingView — Track All Markets
Current ratio of Mural Oncology Plc – BER:IELK2BOB - TradingView — Track All Markets
Mural Oncology Plc Earnings and Revenue – BER:IELK2BOB - TradingView — Track All Markets
Mural Oncology Plc Statistics – BER:IELK2BOB - TradingView — Track All Markets
Mural Oncology Plc Cash Flow – BER:IELK2BOB - TradingView — Track All Markets
MURA SEC FilingsMural Oncology PLC 10-K, 10-Q, 8-K Forms - Stock Titan
Mural Oncology Plc Balance Sheet – BER:IELK2BOB - TradingView — Track All Markets
Mural Oncology Plc Dividends – BER:IELK2BOB - TradingView — Track All Markets
Entry Recap: How Mural Oncology plc stock reacts to oil prices2025 Pullback Review & Weekly Sector Rotation Insights - Улправда
Mural Oncology PLC (NASDAQ:MURA) Receives $12.00 Consensus Price Target from Brokerages - Defense World
How Mural Oncology plc stock reacts to oil pricesJuly 2025 Weekly Recap & Weekly High Potential Stock Alerts - Улправда
Market Recap: Will Mural Oncology plc stock benefit from automationJuly 2025 Review & Real-Time Stock Movement Alerts - Улправда
Will Mural Oncology plc stock outperform value stocksQuarterly Portfolio Report & High Return Trade Guides - Улправда
Is Mural Oncology plc stock positioned for digital transformationJuly 2025 Volume & Low Drawdown Investment Strategies - DonanımHaber
Generation Bio is latest Mass. biotech to be acquired by Xoma - The Business Journals
Xoma Navigates Clinical Setback with Strategic Acquisition - AD HOC NEWS
Xoma completes acquisition of Mural Oncology - MSN
Acorn Capital Advisors LLC Reduces Position in Mural Oncology PLC $MURA - Defense World
Mural Oncology shareholders approve acquisition by XRA 5 Corp. - MSN
Xoma Royalty Expands Portfolio Through Mural Oncology Acquisition - AD HOC NEWS
Mural Oncology Announces Sanction of the Scheme by the High Court - 富途牛牛
XOMA Royalty completes acquisition of Mural Oncology for $2.035 per share - Investing.com Nigeria
XOMA Royalty completes acquisition of Mural Oncology By Investing.com - Investing.com Nigeria
Xoma Completes Acquisition of Mural Oncology - TipRanks
Mural Oncology Announces Effectiveness of Scheme of Arrangement and Completion of Acquisition - Research Tree
Xoma Royalty announces closing of transaction to acquire Mural Oncology plc - marketscreener.com
XOMA Royalty Corporation Completes Acquisition of Mural Oncology plc Under Irish High Court Sanctioned Scheme - Quiver Quantitative
Mural Oncology Plc Completes Acquisition by XRA 5 Corp. - TipRanks
XOMA Royalty Announces Closing of Transaction to Acquire Mural Oncology plc - Yahoo Finance
XOMA Royalty completes acquisition of Mural Oncology - Investing.com India
Mural Oncology plc Announces Effective Date of Scheme Arrangement for Acquisition by XOMA Royalty Corporation - Quiver Quantitative
Mural Oncology (Nasdaq: MURA) scheme with XOMA unit effective as Nasdaq listing ends - Stock Titan
Mural Oncology plc(NasdaqGM: MURA) dropped from S&P TMI Index - marketscreener.com
Mural Oncology plc (MURA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Mural Oncology plc(NasdaqGM: MURA) dropped from NASDAQ Composite Index - marketscreener.com
REGCitadel Group Mural Oncology PLCForm 8.3Mural Oncology plc - TradingView — Track All Markets
XOMA Royalty Corporation completed the acquisition of Mural Oncology plc from group of shareholders. - marketscreener.com
Irish court approves XOMA Royalty’s acquisition of Mural Oncology - Investing.com India
Irish court approves XOMA Royalty’s acquisition of Mural Oncology By Investing.com - Investing.com Australia
Mural Oncology plc Announces Court Approval of Scheme for Acquisition by XOMA Royalty Corporation's Subsidiary - Quiver Quantitative
Mural Oncology (Nasdaq: MURA) wins Irish court nod for XOMA deal, Nasdaq trading expected to end Dec. 4 - Stock Titan
Mural Oncology (MURA) Stock Analysis Report | Financials & Insights - Benzinga
Irish takeover panel lists three companies in offer periods By Investing.com - Investing.com Nigeria
Mural Oncology Plc (MURA) 財務データ
Mural Oncology Plc (MURA) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
0.80%
4.56%
大文字化:
|
ボリューム (24 時間):